FNA250117C15000
- 0.00
- 0.000.00%
Paragon 28 Newsroom
CCORF Maintains Paragon 28(FNA.US) With Buy Rating, Maintains Target Price $15
Paragon 28: Strong Financial Performance, Strategic Positioning, and Innovation Drive 'Buy' Rating
Needham Maintains Paragon 28(FNA.US) With Buy Rating, Maintains Target Price $13
Paragon 28 Analyst Ratings
Needham Reiterates Buy on Paragon 28, Maintains $13 Price Target
Paragon 28 Is Maintained at Buy by Canaccord Genuity
Paragon 28 Price Target Cut to $15.00/Share From $17.00 by Canaccord Genuity
Piper Sandler Maintains Paragon 28(FNA.US) With Buy Rating, Maintains Target Price $12
CCORF Maintains Paragon 28(FNA.US) With Buy Rating, Cuts Target Price to $15
BofA Securities Maintains Paragon 28(FNA.US) With Buy Rating, Maintains Target Price $12
Paragon 28 Analyst Ratings
Needham Maintains Paragon 28(FNA.US) With Buy Rating, Raises Target Price to $13
JMP Securities Maintains Paragon 28(FNA.US) With Buy Rating, Maintains Target Price $20
Buy Rating on Paragon 28: Strong Financial Performance, Strategic Initiatives, and Niche Market Success
Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), ADMA Biologics (ADMA) and Veracyte (VCYT)
Buy Rating Affirmed for Paragon 28 Amid Revenue Growth and Positive EBITDA Outlook
Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Paragon 28 (FNA)
Paragon 28 Analyst Ratings
Needham Maintains Buy on Paragon 28, Lowers Price Target to $11
Buy Rating Affirmed for Paragon 28 Amid Strong Financial Performance and Strategic Growth